Product Description
Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy. It is in the vascular endothelial growth factor (VEGF-A) inhibitors class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK544362/)
Mechanisms of Action: VEGF Inhibitor,Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous,Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Macular Degeneration | Wet Macular Degeneration | Macular Degeneration | Wet Macular Degeneration | Macular Degeneration | Macular Edema | Retinal Degeneration | Retinal Neovascularization | Retinal Vein Occlusion | Wet Macular Degeneration | Choroidal Neovascularization | Edema | Diabetic Retinopathy
Known Adverse Events: Eye Pain | Pain Unspecified | Inflammation | Vitreous Hemorrhage | Hyperemia | Iritis
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Egypt, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Poland, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 34
Highest Development Phases
Phase 3: Diabetic Retinopathy|Macular Degeneration|Macular Edema|Neovascular age-related macular degeneration|Obstetric Labor, Premature|Retinal Degeneration|Retinal Vein Occlusion|Retinopathy of Prematurity|Wet Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GR40549 | P3 |
Unknown Status |
Neovascular age-related macular degeneration |
2029-12-31 |
|
| Portal | P3 |
Recruiting |
Wet Macular Degeneration|Neovascular age-related macular degeneration |
2029-09-30 |
|
| 2020-004427-16 | P3 |
Active, not recruiting |
Neovascular age-related macular degeneration |
2028-10-22 |
|
| YR42983 | P3 |
Recruiting |
Neovascular age-related macular degeneration|Wet Macular Degeneration |
2027-06-30 |